Companies: 10,795·Total market cap: $144.5T
Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc.

IMDXNASDAQHealthcare● Active
$5.72
+$0.48(+9.16%)
Market Cap$153533168
P/E Ratio—
52W High$8.51
52W Low$2.33
SEC Filings

Insight Molecular Diagnostics Inc. (IMDX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001642380 · IMDX · NASDAQ · as of Jun 9, 2026

Filing snapshot

677
Total Filings
10-Q
Latest Form
2026-05-13
Most Recent
2015
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001642380 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-26
Fiscal Year End
Mar 26, 2026
Accession No.
0001642380-26-000004
Primary Document
imdx-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001642380 · Accession 0001642380-26-000004

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-13
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-13Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
10-Q
2026-05-13
View
8-KCurrent Report
8-K
2026-05-13
View
8-K/ACurrent Report (Amended)
8-K/A
2026-05-13
View
ARSARS
ARS
2026-04-30
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-30
View
DEF 14AProxy Statement
DEF 14A
2026-04-30
View
8-KCurrent Report
8-K
2026-04-30
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-04-27
View
10-KAnnual Report
10-K
2026-03-26
View
8-KCurrent Report
8-K
2026-03-26
View
8-KCurrent Report
8-K
2026-02-26
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-02-12
View
8-KCurrent Report
8-K
2026-02-12
View
424B5424B5
424B5
2026-02-11
View
8-KCurrent Report
8-K
2026-02-11
View
Showing 1–15 of 460 filingsForm 4 / 144 hidden· 677 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001642380  |  Exchange: NASDAQ · Healthcare

Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) has submitted 677 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2015. As a Healthcare sector company with CIK 0001642380, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Insight Molecular Diagnostics Inc.'s most comprehensive regulatory disclosure. The most recent Insight Molecular Diagnostics Inc. 10-K was filed on 2026-03-26 for fiscal year ending 2026. Historical IMDX 10-K annual reports are available from 2015 through 2026.

Investors researching Insight Molecular Diagnostics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
CYBN SEC Filings →PRLD SEC Filings →CCCC SEC Filings →ARMP SEC Filings →OABI SEC Filings →CDXS SEC Filings →IVVD SEC Filings →MIST SEC Filings →
→ IMDX Financials→ IMDX Earnings→ IMDX Insider Trades

Frequently Asked Questions

IMDX SEC Filings · 8 questions

Insight Molecular Diagnostics Inc. (IMDX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 677 filings and access original documents at no cost. Insight Molecular Diagnostics Inc.'s CIK is 0001642380.

IMDX SEC filingsInsight Molecular Diagnostics Inc. SEC documentsfind IMDX 10-K